Cantor Fitzgerald Keeps Their Buy Rating on Pfizer (PFE)


In a report released yesterday, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Pfizer (PFE), with a price target of $53. The company’s shares closed on Thursday at $39.38.

Chen observed:

“We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.9% and a 35.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.

Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $48.57.

See today’s analyst top recommended stocks >>

Pfizer’s market cap is currently $225.1B and has a P/E ratio of 21.17. The company has a Price to Book ratio of 3.55.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2019, Mikael Dolsten, the President R&D of PFE bought 309,462 shares for a total of $9,516,355.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts